sorafenib has been researched along with abemaciclib in 5 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (abemaciclib) | Trials (abemaciclib) | Recent Studies (post-2010) (abemaciclib) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 352 | 43 | 343 |
Protein | Taxonomy | sorafenib (IC50) | abemaciclib (IC50) |
---|---|---|---|
Cyclin-T1 | Homo sapiens (human) | 0.0734 | |
Cyclin-K | Homo sapiens (human) | 0.065 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.7586 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.62 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0097 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.7484 | |
Cyclin-A2 | Homo sapiens (human) | 0.1036 | |
G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0048 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.232 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1847 | |
G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0112 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.027 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0693 | |
Cyclin-H | Homo sapiens (human) | 2.6027 | |
CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 3.106 | |
Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0168 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.405 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.405 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 3 (60.00) | 2.80 |
Authors | Studies |
---|---|
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z | 1 |
Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
Laufer, S; Pillaiyar, T | 1 |
4 review(s) available for sorafenib and abemaciclib
Article | Year |
---|---|
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors | 2019 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |
1 other study(ies) available for sorafenib and abemaciclib
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |